Menu
Not yet recruiting NCT06949618

Repetitive Transcranial Magnetic Stimulation in Cancer Pain Management

No phase Interventional Pain Cancer

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Repetitive transcranial magnetic stimulation (rTMS).
Who it may be relevant to
Registry conditions: Pain, Cancer. Basic parameters: 20 years — 70 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Taiwan
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

Feasibility and Effectiveness of Repetitive Transcranial Magnetic Stimulation in Patients With Cancer Pain

Overview

Over half of cancer patients experience cancer-related pain. Despite advances in pain management with opioids, many patients continue to suffer from chronic cancer pain. The underlying mechanisms of cancer-related pain remain poorly understood, but they may be linked to brain neuroplasticity. As a result, some researchers suggest that targeting the motor cortex in cancer patients could improve pain management. However, few studies have investigated the effectiveness of remodeling neuroplasticity with repetitive transcranial magnetic stimulation (rTMS) to reduce cancer-related pain. To validate the use of rTMS in cancer-related pain, we plan to conduct a randomized controlled trial involving 30 cancer pain patients. Participants will be randomly assigned to receive either rTMS or sham rTMS treatment. Functional magnetic resonance imaging (fMRI) and pain index assessments will be conducted before and after the treatment to evaluate the outcomes.

Interventions

  • Device Repetitive transcranial magnetic stimulation (rTMS)
    Repetitive transcranial magnetic stimulation toward for cancer pain (real and sham control)

Primary outcome measures

  • Brief Pain Inventory, BPI [Time frame: Assess the BPI outcome before the intervention, after 1 week and 2 weeks of intervention, as well as 1 week and 4 weeks after the intervention is completed.]
  • McGill Pain Questionnaire [Time frame: Assess MPQ scores before the intervention, after 1 week and 2 weeks of intervention, as well as 1 week and 4 weeks after the intervention is completed.]
Secondary outcome measures (5)
  • Numerical Rating Scale, NRS [Time frame: Assess the NRS scale before the intervention, after 1 week and 2 weeks of intervention, as well as 1 week and 4 weeks after the intervention is completed.]
  • Visual Analogue Scale , VAS [Time frame: Assess the VAS scale before the intervention, after 1 week and 2 weeks of intervention, as well as 1 week and 4 weeks after the intervention is completed.]
  • Resting-state functional imaging, rsfMRI [Time frame: Assess the fMRI results before the intervention and after 2 weeks of interventions.]
  • Beck Depression Inventory, BDI [Time frame: Assess the BDI scale before the intervention, after 1 week and 2 weeks of intervention, as well as 1 week and 4 weeks after the intervention is completed.]
  • The 36-Item Short Form Survey quality of life [Time frame: Assess the The SF-36 outcome before the intervention, after 1 week and 2 weeks of intervention, as well as 1 week and 4 weeks after the intervention is completed.]

Eligibility criteria

Inclusion criteria

  • Patients have cancer pain symptoms, confirmed by a physician as cancer pain or neuropathic cancer pain
  • Experienced the worst pain NRS score ≥ 4
  • The patient demonstrate good cognition and is able to cooperate with the assessment of pain severity.
  • The estimated survival time exceeds 3 months.
  • Pre-existing bisphosphonate, chemotherapy, and hormonal therapy regimens remained unchanged throughout the study.

Exclusion criteria

  • Individuals who have undergone head surgery or have metal implants in the head.
  • Individuals with implanted cardiac pacemakers or cochlear prostheses.
  • Have a history of epilepsy.
  • Patients diagnosed with primary brain tumors or metastatic brain lesions.
  • Present with additional neurological, psychiatric, or severe medical disorders.
  • Individuals with metallic implants located in the cranial or cervical regions.
  • Women who are pregnant.
  • Presence of acute pain in any body region attributable to other medical conditions. -

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Double blind
Primary purpose
Treatment

Study locations

Taiwan · 1 center
  • Taipei Medical University Hospital — Taipei

Identifiers

NCT: NCT06949618 · N202209046

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗